Qinyang Wang

Prof. Qinyang Wang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Advanced Science
Verified
Journal Article
Open access
HYHao Yin
Hao Yin
TCTanzhou Chen
Tanzhou Chen
XHXiaoqu Hu
Xiaoqu Hu
WZWenting Zhu
Wenting Zhu
YLYida Li
Yida Li
QWQinyang Wang
Qinyang Wang
Pyroptosis can effectively overcome immunosuppression and reactivate antitumor immunity. However, pyroptosis initiation is challenging. First, the underlying biological mechanisms of pyroptosis are complex, and a variety of gasdermin family proteins can be targeted to induce pyroptosis. Second, other intracellular death pathways may also interfere with pyroptosis. The rationally designed gasdermin protein‐targeting biomaterials are capable of inducing pyroptosis and have the capacity to stimulate antitumor immune function in a safe and effective manner. This review provides a comprehensive overview of the design, function, and antitumor efficacy of pyroptosis‐inducing materials and the associated challenges, with a particular focus on the design options for pyroptosis‐inducing biomaterials based on the activation of different gasdermin proteins. This review offers a valuable foundation for the further development of pyroptosis‐inducing biomaterials for clinical applications.

6 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZZZhigui Zuo
Zhigui Zuo
HYHao Yin
Hao Yin
YZYu Zhang
Yu Zhang
CXCongying Xie
Congying Xie
QWQinyang Wang
Qinyang Wang
Lytic cell death triggers an antitumour immune response. However, cancer cells evade lytic cell death by several mechanisms. Moreover, a prolonged and uncontrolled immune response conversely leads to T-cell exhaustion. Therefore, an oncolytic system capable of eliciting an immune response by killing cancer cells in a controlled manner is needed. Here, we establish a micro-scale cytotoxic T-cell-inspired oncolytic system (TIOs) to precisely lyse cancer cells by NIR-light-controlled lipid peroxidation. Our TIOs present antigen-based cell recognition, tumour-targeting and catalytic cell-lysis ability; thus, the TIOs induce oncolysis in vivo. We apply TIOs to preclinical cancer models, showing anti-tumor activity with negligible side-effects. Tumour regression is correlated with a T-cell based anti-tumour immune response and TIOs also improve responses to anti-PD-1 therapy or STING activation. Our study provides insights to design oncolytic systems for antitumour immunity. Moreover, activation of STING can reverse T-cell exhaustion in oncolysis.

29 March 2024 in Advanced Materials
Verified
Journal Article
Closed access
HYHao Yin
Hao Yin
XHXiaoqu Hu
Xiaoqu Hu
CXCongying Xie
Congying Xie
YLYida Li
Yida Li
YGYanjun Gao
Yanjun Gao
QWQinyang Wang
Qinyang Wang

28 December 2023 in Advanced Materials
Verified
Journal Article
Closed access
HYHao Yin
Hao Yin
CXCongying Xie
Congying Xie
ZZZhigui Zuo
Zhigui Zuo
DXDanli Xie
Danli Xie
QWQinyang Wang
Qinyang Wang

14 March 2024 in Advanced Science
Verified
Journal Article
Open access
XHXiaoqu Hu
Xiaoqu Hu
HYHao Yin
Hao Yin
DXDanli Xie
Danli Xie
TCTanzhou Chen
Tanzhou Chen
YLYida Li
Yida Li
QWQinyang Wang
Qinyang Wang
The Gasdermin protein is a membrane disruptor that can mediate immunogenic pyroptosis and elicit anti‐tumor immune function. However, cancer cells downregulate Gasdermin and develop membrane repair mechanisms to resist pyroptosis. Therefore, an artificial membrane disruptor (AMD) that can directly mediate membrane rupture in pyroptosis‐deficient cells and induce antitumor immune responses in a controllable manner will be valuable in preclinical and clinical research. A micron‐scale Ce6‐based AMD that can directly induce plasma membrane rupture (PMR) in gasdermin‐deficient tumor cells is established. Micron‐scale AMDs localize Ce6 specifically to the plasma membrane without labeling other organelles. Compared to free Ce6 molecules, the use of AMDs results in a higher degree of specificity for the plasma membrane. Due to this specificity, AMDs mediate fast and irreversible PMR under 660 nm red light. Furthermore, the AMDs are capable of inducing programmed cell death and lytic cell death in a catalytic manner, demonstrating that the amount of Ce6 used by AMDs is only one‐fifth of that used by Ce6 alone when inducing 80% of cancer cell death. In vivo, the AMDs show specificity for tumor targeting and penetration, suggesting that light‐driven programmed cell death is specific to tumors. AMDs are applied to antitumor therapy in gasdermin‐deficient tumors, resulting in efficient tumor elimination with minimal damage to major organs when combined with anti‐PD‐1 therapy. Tumor regression is correlated with PMR‐mediated inflammation and T‐cell‐based immune responses. This study provides new insights for designing bioinspired membrane disruptors for PMR and mediating anti‐tumor immunotherapy. Additionally, AMD is a dependable tool for examining the immunogenicity of PMR both in vitro and in vivo.

10 October 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
QWQinyang Wang
Qinyang Wang
XHXiaoqu Hu
Xiaoqu Hu
HYHao Yin
Hao Yin
TCTanzhou Chen
Tanzhou Chen
DXDanli Xie
Danli Xie
MLMingdong Lu
Mingdong Lu
Gasdermin protein, a membrane disruptor, can mediate immunogenic pyroptosis and elicit anti-tumour immune function. However, cancer cells downregulate gasdermin and develop membrane repair mechanisms to resist pyroptosis. Therefore, an artificial membrane disruptor (AMD) that can directly mediate membrane rupture in pyroptosis-deficient cells and induce antitumour immune responses in a controllable manner is valuable in preclinical and clinical research. Here, we have established a micron-scale Ce6-based artificial membrane disruptor (AMD) to directly induce plasma membrane rupture (PMR) in gasdermin-deficient tumour cells. Compared to free Ce6 molecules, micron-scale AMDs specifically localised Ce6 to the plasma membrane without labelling other organelles. Due to the plasma membrane specificity, AMDs mediated irreversible and fast PMR under 660 nm red light. In addition, our AMDs were able to mediate PMR and lytic cell death in a catalytic manner, such that the Ce6 used by AMDs is one-fifth that of Ce6 alone when mediating 80% of cancer cell death. In vivo, our AMDs exhibited tumour targeting and penetration, indicating that light-driven PMR was tumour specific. We applied AMDs to antitumour therapy in gasdermin-deficient tumours, the results showed that all tumours could be efficiently eliminated with negligible damage to major organs by synergising with anti-PD-1 therapy. Tumour regression was correlated with PMR-mediated inflammation and T-cell-based immune responses. Our study provides new insights for designing the bioinspired membrane disruptor for PMR and mediating anti-tumour immunotherapy. In addition, AMD is a reliable tool for investigating the immunogenicity of PMR in vitro and in vivo.